Daniel Ribes

Daniel Ribes

Senior Health Economist and AI / GenAI Engineer

I build the economic models that pricing and access decisions rest on, and the AI systems that make evidence work faster and easier to check.

Get in touch GitHub projects Download CV
Years in HEOR
10+
HTA bodies
NICE, NCPE, SMC
Languages
7
Based in
Barcelona
Illustrative Kaplan–Meier survival curves Two stepped survival curves over ten years. The new treatment stays above the comparator, and the shaded area between them represents the survival gained. 0 2 4 6 8 10 Years 1.0 0.5 0 New treatment Comparator Survival gained
Every cost-effectiveness question starts with the gap between two curves. Illustrative Kaplan–Meier estimate, not trial data.

About

Senior Health Economist and AI engineer with 10+ years bridging rigorous HEOR methodology, advanced analytics and software engineering. I have led HTA submissions to NICE, NCPE and SMC and built cost-effectiveness, budget impact, partitioned-survival, Markov and dynamic-transmission models across oncology, rare disease, cardiometabolic and renal conditions.

Since November 2025 I have delivered a portfolio of freelance HEOR models alongside production-grade generative-AI systems: retrieval-augmented evidence agents, multi-model LLM orchestration and automated evidence-to-deliverable pipelines. In 2026 I completed a Master's in Data Science & AI with First-class Honors.

My background is unusual for the field. I trained as an agricultural engineer, then as a health economist, then as a blockchain developer, and I have worked and studied in Spain, the UK, Switzerland, the Netherlands and Belgium.

  • HTA track record

    Submissions to NICE, NCPE and SMC for clients including BeiGene, Pharmanovia and UCB.

  • GenAI for evidence

    RAG evidence agents, MCP servers and multi-model LLM orchestration built for HEOR work.

  • Models people can audit

    Transparent Excel/VBA, R and Python models, with independent QC of client models.

Expertise

Economic modeling & HTA

Cost-effectiveness and budget impact models for NICE, NCPE and SMC submissions.

  • Partitioned survival models
  • Markov, semi-Markov & microsimulation
  • Dynamic transmission models
  • PSA, OWSA & DSA

Survival & statistics

Survival analysis and parametric modeling to interpret clinical data.

  • Parametric survival extrapolation
  • Kaplan–Meier analysis
  • Hazard ratio estimation

Evidence synthesis

Literature reviews and network meta-analysis to support value propositions.

  • Bayesian & frequentist NMA
  • Indirect comparisons (MAIC, Bucher, STC)
  • Real-world evidence

Pricing & market access

Pricing strategy, reimbursement dossiers and value communication tools.

  • Global value dossiers
  • Pricing negotiation tools
  • Market access strategy

AI, GenAI & blockchain

Generative-AI systems and machine learning for evidence work.

  • RAG & LLM agents (LangGraph, ChromaDB)
  • MCP servers & multi-model orchestration
  • scikit-learn, PyTorch, SHAP
  • Solidity & Hyperledger

Programming

Full-stack skills applied to modeling and tool building.

  • R
  • Python
  • VBA
  • C++
  • Julia
  • SQL
  • TypeScript
  • FastAPI
  • Docker
  • Power BI
  • WinBUGS

What I deliver

  • HTA submissions & dossiers. NICE technology appraisals, global value dossiers and payer objection handlers.
  • Economic models. Cost-effectiveness, budget impact and dynamic transmission models.
  • Pricing & access strategy. Pricing strategy, portfolio pricing models and access planning.
  • Evidence synthesis. Network meta-analyses, systematic literature reviews and real-world evidence.
  • AI integration. Workflow automation, predictive analytics and RAG evidence agents.
  • Custom tools. Excel/VBA applications, interactive dashboards and R/Python packages.

Therapeutic areas

Oncology
Prostate cancer, RCC, NSCLC, lymphoma, NETs, CAR-T
Rare diseases
Cushing's syndrome, sickle cell disease, hepatitis delta
Cardiometabolic & renal
Obesity, diabetes, Lp(a) / CVD, CKD
Vaccines
RSV, infectious disease prevention
Autoimmune
Rheumatic diseases, biologics
MedTech
Cardiac devices, PFO closure

Selected work

2026

Master's final project

España en escenarios

A transparent macro-fiscal simulation and AI-model evaluation platform for Spain. It shows what a set of assumptions on interest rates, growth, public balance and demographics implies for debt, housing and twelve household profiles. Defended in September 2026 for the Master's in Data Science & AI at Evolve.

  • Semi-structural scenario engine in Python and TypeScript with stochastic debt projections
  • Regional housing models with bootstrap uncertainty
  • Gradient-boosting sovereign-default classifier explained with SHAP
  • RAG assistant that answers with cited passages, on dated data cut-offs with reproducible builds
  • Python
  • TypeScript
  • Monte Carlo
  • RAG
Open the project

2025 – present

AI engineer, DANRIBES S.L.

GenAI for HEOR: evidence agents and model QC

Generative-AI systems that speed up evidence generation and check health economic models.

  • RAG evidence agents (LangGraph, ChromaDB, Streamlit) that answer clinical and HEOR questions with sources
  • AI-versus-rule-based model QC benchmark: a 100-error fault library across 72 seeded models with a VBA detection engine
  • HEOR Studio, an AI-native toolkit of skills, MCP servers and workflows that builds documented R and Excel models
  • ISPOR 2026 abstract and poster on a human-in-the-loop AI QC workflow for HEOR Excel models
  • LangGraph
  • MCP
  • Python
  • Excel/VBA

2021 – 2024

Lead modeler, GSK

Arexvy RSV dynamic transmission model

Epidemiologic and pharmacoeconomic models for Arexvy, the RSV vaccine for older adults, supporting global market access.

  • Hybrid Excel / R / C++ architecture with ODE-based dynamic transmission
  • Multi-country model that adapts to different demographics
  • Aligned with ICON PLC and RTI on the global value dossier
  • Informed vaccination timing and target population decisions
  • Excel/VBA
  • R (ODEs)
  • C++

2021 – 2024

Model developer, with CHESS

RSV static cost-effectiveness and budget impact models

Static CEM and BIM built for multiple country adaptations.

  • Flexible architecture for market localisation
  • ICER and QALY estimation with scenario and sensitivity analysis
  • Integrated budget impact projections for payers
  • Excel
  • VBA

2020 – 2021

HEOR manager, Novartis Oncology

NET portfolio budget impact model

A portfolio approach for neuroendocrine tumours that allows flexible pricing across several products.

  • Pricing mechanisms with volume capping and portfolio discounts
  • Matrix engine linking patient flow to survival data
  • Real-time scenarios for payer negotiations, adapted for Canada and LATAM
  • VBA engine
  • Budget impact

2018 – 2020

Model developer, Wellmera

Cushing's syndrome semi-Markov model

A non-homogeneous semi-Markov cohort model estimating the cost-effectiveness of osilodrostat (LCI699) in Finland.

  • 262-state engine based on treatment history and response
  • Executive interface for non-technical users
  • "World with / without" scenarios, tornado analysis and patient flow charts
  • Excel/VBA
  • Semi-Markov

More code, models and dashboards are on GitHub.

Publications

Experience

  1. Nov 2025 – present

    Freelance HEOR Modeler & AI Engineer

    DANRIBES S.L., Barcelona (remote)

    Oncology CAR-T cost-effectiveness and multi-line lymphoma budget impact models, independent model QC and VBA audits, ITC/NMA feasibility tooling, and GenAI systems for evidence work.

  2. Jul – Oct 2025

    Engagement Manager

    IQVIA, Barcelona (remote)

    Projects with the IQVIA Core Obesity Model and integrated Obesity–Diabetes Model across 20+ year cardiometabolic horizons.

  3. Oct 2024 – Jul 2025

    HTA Modeler & AI Integration Project Lead

    AXIS Consulting UK, Barcelona (remote)

    Coordinated HTA submissions to NICE, NCPE and SMC, and brought AI into consultancy workflows to cut manual evidence work.

  4. Jul 2021 – Oct 2024

    Lead Modeler, Arexvy RSV

    GSK (freelance), Barcelona (remote)

    Dynamic transmission, static cost-effectiveness and budget impact models for the Arexvy vaccine.

  5. Jun 2020 – Jun 2021

    Region Europe HEOR Manager

    Novartis Oncology, Basel

    Supported country affiliates with HTA submissions, built pricing constructs and set up a HEOR Centre of Excellence.

  6. Mar 2018 – May 2020

    Health Economist Modeler, Head

    Wellmera AG, Basel

    Built a 262-state semi-Markov model for Cushing's syndrome and published research on acute kidney injury interventions.

  7. 2015 – 2018

    Health Economist Modeler

    Envision Pharma–Curo, Wickenstones and Novartis Oncology (intern), UK

    Health economic modeling for pharmaceutical clients after the MSc in Health Economics.

Education

  1. 2026

    Master's in Data Science & AI With First-class Honors

    Evolve

    Python, machine learning, deep learning, NLP, LLMs and RAG. Verify certificate

  2. 2024

    Master in Blockchain Development

    Codecrypto Academy, Madrid

    Full stack, DevOps, Solidity and Hyperledger.

  3. 2017

    Advanced Modelling Methods for Economic Evaluation

    Centre for Health Economics, University of York

  4. 2014 – 2015

    MSc in Health Economics With Distinction

    City, University of London

  5. 2005 – 2006

    Management Development Program (PDD)

    IESE Business School, Universidad de Navarra

  6. 1986 – 1993

    MSc in Agricultural Engineering

    UPC Barcelona and Wageningen University (Erasmus)

Languages

  • SpanishNative
  • CatalanNative
  • EnglishFluent
  • FrenchAdvanced
  • ItalianAdvanced
  • PortugueseIntermediate
  • GermanBasic

Have a model to build, check or speed up?

I design transparent HEOR models that inform pricing and access decisions, and I use AI to make evidence generation faster. Write to me about your project.

danribes@iies.es
Phone
+34 696 62 83 77
Location
Barcelona, Spain. Working remotely.
LinkedIn
Daniel Ribes
GitHub
danribes
CV
Download CV